Drugs / Pyrvinium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06782048 | Aug 2025 → Dec 2029 expected | gastric neoplasm | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06590454 Comparator | Dec 2025 → Oct 2026 expected | gastric intestinal metaplasia | Katherine Garman | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyrvinium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06782048 ↗ |
| Route | Oral | “Following the initial endoscopy, participants will receive placebo or Pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.” NCT06590454 ↗ |